Aryl hydrocarbon receptor and lung cancer

Anticancer Research

Volumn 33, Issue 4, 2013, Pages 1247-1256

  Tsay, Junchieh J ^a   Tchou Wong, Kam Meng ^a   Greenberg, Alissa K ^a   Pass, Harvey ^a   Rom, William N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aryl hydrocarbon receptor; Cigarette smoke; Dioxin; Lung cancer; Polycyclic aromatic hydrocarbons; Review; Tumorigenesis

Indexed keywords

ANGIOPOIETIN 2; AROMATIC HYDROCARBON RECEPTOR; CYCLOOXYGENASE 2; CYTOCHROME P450; CYTOCHROME P450 1A1; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR; HEAT SHOCK PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; OSTEOPONTIN; PROSTAGLANDIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; B LYMPHOCYTE; CANCER GROWTH; CANCER RISK; CELL ADHESION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DNA POLYMORPHISM; ENZYME MECHANISM; HUMAN; INFLAMMATION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; XENOBIOTIC METABOLISM;

ANIMALS; HUMANS; LUNG NEOPLASMS; RECEPTORS, ARYL HYDROCARBON;

EID: 84876765634     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Nebert DW, Goujon FM and Gielen JE: Ayrl hydrocarbon hydroxylase induction by polycyclic aromatic hydrocarbons: Simple autosomal dominant trait in the mouse. Nature 236: 107-110, 1972.
3. Poland A and Knutson JC: 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Parmacol Toxicol 22: 517-554, 1982.
4. Denison MS, Pandini A, Nagy SR, Baldwin EP and Bonati L: Ligand binding and activation of the Ah receptor. Chem Biol Interact 141: 3-24, 2002. (Pubitemid 35229988)
5. Kozak KR, Abbott B and Hankinson O: ARNT-deficient mice and placental differentiation. Dev Biol 191: 297-305, 1997. (Pubitemid 28282914)
6. Haarmann-Stemmann T and Abel J: The arylhydrocarbon receptor repressor (AhRR): structure, expression, and function. Biol Chem 387: 1195-1199, 2006. (Pubitemid 44402065)
7. Chiba T, Uchi H, Yasukawa F, Furue M: Role of the arylhydrocarbon receptor in lung disease. Int Arch Allergy Immunol 155(Suppl 1): 129-134, 2011.
8. Wong PS, Vogel CF, Kokosinski K and Matsumura F: Arylhydrocarbon receptor activation in NCI-H441 cells and C57BL/6 mice: possible mechanisms for lung dysfunction. Am J Respir Cell Mol Biol 42: 210-217, 2010.
9. Chiba T, Uchi H, Tsuji G, Gondo H, Moroi Y and Furue M: Arylhydrocarbon receptor (AhR) activation in airway epithelial cells induces MUC5AC via reactive oxygen species (ROS) production. Pulm Pharmacol Ther 24: 133-140, 2011.
10. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M and Weiner HL: Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453: 65-71, 2008. (Pubitemid 351630328)
11. Rodriguez-Antona C and Ingelman-Sundberg M: Cytochrome P450 pharmacogenetics and cancer. Oncogene 25: 1679-1691, 2006.
12. Anttila S, Raunio H and Hakkola J: Cytochrome P450-mediated pulmonary metabolism of carcinogens: Regulation and cross-talk in lung carcinogenesis. Am J Respir Cell Mol Biol 44: 583-590, 2011.
13. Willey JC, Coy EL, Frampton MW and Torres A: Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am J Respir Cell Mol Biol 17: 114-124, 1997. (Pubitemid 127500828)
14. Uppstad H, Ovrebo S, Haugen A and Mollerup S: Importance of CYP1A1 and CYP1B1 in bioactivation of benzo[a]pyrene in human lung cell lines. Toxicol Lett 192: 221-228, 2010.
15. Hayden MS and Ghosh S: Signaling to NF-kappaB. Genes Dev 18: 2195-2224, 2004.
16. Tian Y, Rabson AB and Gallo MA: Ah receptor and NF-kappaB interactions: mechanisms and physiological implications. Chem Biol Interact 141: 97-115, 2002. (Pubitemid 35223207)
17. Camacho IA, Singh N, Hegde VL, Nagarkatti M and Nagarkatti PS: Treatment of mice with 2,3,7,8-tetrachlorodibenzo-p-dioxin leads to aryl hydrocarbon receptor-dependent nuclear translocation of NF-kappaB and expression of Fas ligand in thymic stromal cells and consequent apoptosis in T-cells. J Immunol 175: 90-103, 2005. (Pubitemid 40884305)
18. Schlezinger JJ, Blickarz CE, Mann KK, Doerre S and Stegeman JJ: Identification of NF-kappaB in the marine fish Stenotomus chrysops and examination of its activation by aryl hydrocarbon receptor agonists. Chem Biol Interact 126: 137-157, 2000. (Pubitemid 30336362)
19. Chen PH, Chang H, Chang JT and Lin P: Aryl hydrocarbon receptor in association with RelA modulates IL-6 expression in non-smoking lung cancer. Oncogene 31: 2555-2565, 2012.
20. Thatcher TH, Maggirwar SB, Baglole CJ, Lakatos HF, Gasiewicz TA, Phipps RP and Sime PJ: Aryl hydrocarbon receptor-deficient mice develop heightened inflammatory responses to cigarette smoke and endotoxin associated with rapid loss of the nuclear factor-kappaB component RelB. Am J Pathol 170: 855-864, 2007. (Pubitemid 47339355)
21. Baglole CJ, Maggirwar SB, Gasiewicz TA, Thatcher TH, Phipps RP and Sime PJ: The aryl hydrocarbon receptor attenuates tobacco smoke-induced cyclooxygenase-2 and prostaglandin production in lung fibroblasts through regulation of the NF-kappaB family member RelB. J Biol Chem 283: 28944-28957, 2008.
22. Lewis KN, Mele J, Hayes JD and Buffenstein R: Nrf2, a guardian of healthspan and gatekeeper of species longevity. Integr Comp Biol 50: 829-843, 2010.
23. Garber K: Biochemistry: A radical treatment. Nature 489: S4-6, 2012.
24. Miao W, Hu L, Scrivens PJ and Batist G: Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J Biol Chem 280: 20340-20348, 2005. (Pubitemid 40776732)
25. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A and Abnet CC: Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 9: 649-656, 2008.
26. Henschke CI and Miettinen OS: Women's susceptibility to tobacco carcinogens. Lung Cancer 43: 1-5, 2004. (Pubitemid 38096286)
27. Mollerup S, Berge G, Baera R, Skaug V, Hewer A, Phillips DH, Stangeland L and Haugen A: Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. Int J Cancer 119: 741-744, 2006. (Pubitemid 44051435)
28. Patel JD, Bach PB and Kris MG: Lung cancer in us women: A contemporary epidemic. JAMA 291: 1763-1768, 2004. (Pubitemid 38489898)
29. Uppstad H, Osnes GH, Cole KJ, Phillips DH, Haugen A and Mollerup S: Sex differences in susceptibility to PAHs is an intrinsic property of human lung adenocarcinoma cells. Lung Cancer 71: 264-270, 2011.
30. Kreuzer M, Boffetta P, Whitley E, Ahrens W, Gaborieau V, Heinrich J, Jockel KH, Kreienbrock L, Mallone S, Merletti F, Rosesch F, Zambon P and Simonato L: Gender differences in lung cancer risk by smoking: a multicentre case-control study in Germany and Italy. Br J Cancer 82: 227-233, 2000. (Pubitemid 30008986)
31. Zang EA and Wynder EL: Differences in Lung Cancer Risk Between Men and Women: Examination of the Evidence. J Natl Cancer Inst 88: 183-192, 1996. (Pubitemid 26065830)
32. Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ and Miller AB: Are Female Smokers at Higher Risk for Lung Cancer than Male Smokers?: A Case-Control Analysis by Histologic Type. Am J Epidemiol 138: 281-293, 1993. (Pubitemid 23263599)
33. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, Takahashi S, Kouzmenko A, Nohara K, Chiba T, Fujii-Kuriyama Y and Kato S: Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446: 562-5666, 2007.
34. Ohtake F, Takeyama K, Matsumoto T, Kitagawa h, Yamamoto Y, Nohara K, Tohyama C, Krust A, Mimura J, Chambon P, Yanagisawa J, Fujii-Kuriyama Y and Kato S: Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423: 545-550, 2003. (Pubitemid 36648579)
35. Cui R, Takahashi F, Ohashi R, Denison MS, Pandini A, Nagy SR, Baldwin EP and Bonati L: Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 63: 368-374, 2009.
36. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF and Casson AG: Osteopontin expression in lung cancer. Lung Cancer 15: 311-323, 1996. (Pubitemid 26399511)
37. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M and Abe S: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160: 1269-1273, 1999. (Pubitemid 29487470)
38. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S and Donington JS: Reduction of Elevated Plasma Osteopontin Levels With Resection of Non-Small-Cell Lung Cancer. Clin Oncol 28: 936-941, 2010.
39. Goparaju CM, Pass HI, Blasberg JD, Hirsch N and Donington JS: Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 5: 1516-1523, 2010.
40. Blasberg JD, Goparaju CM, Pass HI and Donington JS: Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 139: 1587-1593, 2010.
41. Chuang CY, Chang H, Lin P, Sun SJ, Chen PH, Lin YY, Sheu GT, Ko JL, Hsu SL and Chang JT: Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer. Gene 492: 262-269, 2012.
42. Knerr S and Schrenk D: Carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p- dioxin in experimental models. Mol Nutr Food Res 50: 897-907, 2006. (Pubitemid 44621795)
43. Dietrich C and Kaina B: The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 31: 1319-1328, 2010.
44. Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, Fujii-Kuriyama Y and Ishikawa T: Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 97: 779-782, 2000. (Pubitemid 30070386)
45. Shi S, Yoon DY, Hodge-Bell KC, Bebenek IG, Whitekus MJ, Zhang R, Cochran AJ, Huerta-Yepez S, Yim SH, Gonzalez FJ, Jaiswal AK and Hankinson O: The aryl hydrocarbon receptor nuclear translocator (Arnt) is required for tumor initiation by benzo[a]pyrene. Carcinogenesis 30: 1957-1961, 2009.
46. Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N and Borlak J: Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect 114: 1655-1661, 2006. (Pubitemid 44718269)
47. Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT and Sutter TR: Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and exsmokers. Toxicol Appl Pharmacol 199: 210-219, 2004. (Pubitemid 39208722)
48. Matsumoto Y, Ide F, Kishi R, Akutagawa T, Sakai S, Nakamura M, Ishikawa T, Fujii-Kuriyama Y and Nakatsuru Y: Aryl Hydrocarbon Receptor Plays a Significant Role in Mediating Airborne Particulate-Induced Carcinogenesis in Mice. Environ Sci Tech 41: 3775-3780, 2007. (Pubitemid 350067228)
49. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R and Lubet RA: Expression of CYP1A1 gene in patients with lung cancer: Evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 82: 1333-1339, 1990. (Pubitemid 20238488)
50. Oyama T, Sugio K, Uramoto H, Kawamoto T, Kagawa N, Nadaf S, Carbone D and Yasumoto K: Cytochrome P450 expression (CYP) in non-small cell lung cancer. Front Biosci 12: 2299-2308, 2007.
51. Lin P, Chang H, Ho WL, Wu MH and Su JM: Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human non-small cell lung cancers. Lung Cancer 42: 255-261, 2003. (Pubitemid 37468537)
52. Nerurkar PV, Schut HA, Anderson LM, Riggs CW, Fornwald LW and Davis CD: Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction. Mol Pharmacol 49: 874-881, 1996. (Pubitemid 26146144)
53. Revel A, Raanani H, Younglai E, Xu J, Rogers I, Han R, Savouret JF and Casper RF: Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol 23: 255-261, 2003. (Pubitemid 36950295)
54. Sagredo C, Ovrebo S, Haugen A, Fujii-Kuriyama Y, Baera R, Botnen IV and Mollerup S: Quantitative analysis of benzo[a]pyrene biotransformation and adduct formation in Ahr knockout mice. Toxicol Lett 167: 173-182, 2006. (Pubitemid 44780046)
55. Chen W, Li Z, Bai L and Lin Y: NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci 16: 1172-1185, 2011.
56. Wong KK, Jacks T and Dranoff G: NF-kappaB fans the flames of lung carcinogenesis. Cancer Prev Rev 3: 403-405, 2010.
57. Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB and Wistuba, II: Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107: 2637-2646, 2006. (Pubitemid 44845619)
58. Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A and Dubinett S: Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 11: 7674-7682, 2005. (Pubitemid 41611609)
59. Gao SG, Dong XY, Wang LJ and He J: [The study on the chromosome aneuploidy in human lung cancer]. Zhonghua Yi Xue Za Zhi 87: 1701-1703, 2007. (Pubitemid 47316240)
60. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, Sharma S and Dubinett SM: Smoking and Lung Cancer: The Role of Inflammation. Proc Amer Thorac Soci 5: 811-815, 2008.
61. Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ and Subbaramaiah K: Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 7: 2669-2674, 2001. (Pubitemid 32911370)
62. Brown JR and DuBois RN: Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10: 4266s-4269s, 2004. (Pubitemid 38812460)
63. Kim HS, Youm HR, Lee JS, Min KW, Chung JH and Park CS: Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 42: 163-170, 2003.
64. Martey CA, Baglole CJ, Gasiewicz TA, Sime PJ and Phipps RP: The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts. American Journal of Physiology - Lung Cellular and Molecular Physiology 289: L391-L399, 2005. (Pubitemid 41192713)
65. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M and Hirohashi S: Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105: 13568-13573, 2008.
66. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M and Hirohashi S: Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68: 1303-1309, 2008. (Pubitemid 351346836)
67. Broët P, Dalmasso C, Tan EH, Alifano M, Zhang S, Wu J, Lee MH, Régnard J-F, Lim D, Koong HN, Agasthian T, Miller LD, Lim E, Camilleri-Broët S and Tan P: Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma. Clinical Cancer Research 17: 3542-3550, 2011.
68. Ruosaari ST, Nymark PE, Aavikko MM, Kettunen E, Knuutila S, Hollmen J, Norppa H and Anttila SL: Aberrations of chromosome 19 in asbestos-associated lung cancer and in asbestos-induced micronuclei of bronchial epithelial cells in vitro. Carcinogenesis 29: 913-917, 2008. (Pubitemid 351982233)
69. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ and Wistuba II: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16: 3743-3753, 2010.
70. Satoh H, Moriguchi T, Taguchi K, Takai J, Maher JM, Suzuki T, Winnard PT, Raman V, Ebina M, Nukiwa T and Yamamoto M: Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 31: 1833-1843, 2010.
71. Muscarella LA, Parrella P, D'Alessandro V, la Torre A, Barbano R, Fontana A, Tancredi A, Guarnieri V, Balsamo T, Coco M, Copetti M, Pellegrini F, De Bonis P, Bisceglia M, Scaramuzzi G, Maiello E, Valori VM, Merla G, Vendemiale G and Fazio VM: Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 6: 710-719, 2011.
72. Li QK, Singh A, Biswal S, Askin F and Gabrielson E: KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. J Hum Genet 56: 230-234, 2011.
73. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV and Biswal S: Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420, 2006.
74. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S and Yamamoto M: Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21: 689-700, 2006. (Pubitemid 43290735)
75. Hanahan D and Weinberg Robert A: Hallmarks of Cancer: The Next Generation. Cell 144: 646-674, 2011.
76. Shimba S, Komiyama K, Moro I and Tezuka M: Overexpression of the aryl hydrocarbon receptor (AhR) accelerates the cell proliferation of A549 cells. J Biochem 132: 795-802, 2002. (Pubitemid 35408504)
77. Ramakrishna G and Anderson LM: Levels and membrane localization of the c-K-ras p21 protein in lungs of mice of different genetic strains and effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and Aroclor 1254. Carcinogenesis 19: 463-470, 1998. (Pubitemid 28375449)
78. Beebe LE, Kim YE, Amin S, Riggs CW, Kovatch RM and Anderson LM: Comparison of transplacental and neonatal initiation of mouse lung and liver tumors by N-nitrosodimethylamine (NDMA) and 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone (NNK) and promotability by a polychlorinated biphenyls mixture (Aroclor 1254). Carcinogenesis 14: 1545-1548, 1993. (Pubitemid 23249356)
79. Diry M, Tomkiewicz C, Koehle C, Coumoul X, Bock KW, Barouki R and Transy C: Activation of the dioxin/aryl hydrocarbon receptor (AhR) modulates cell plasticity through a JNK-dependent mechanism. Oncogene 25: 5570-5574, 2006. (Pubitemid 44344107)
80. Rico de Souza A, Zago M, Pollock SJ, Sime PJ, Phipps RP and Baglole CJ: Genetic ablation of the aryl hydrocarbon receptor causes cigarette smoke-induced mitochondrial dysfunction and apoptosis. J Biol Chem 286: 43214-43228, 2011.
81. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA and Simon MC: Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386: 403-407, 1997. (Pubitemid 27154481)
82. Roman AC, Carvajal-Gonzalez JM, Rico-Leo EM and Fernandez-Salguero PM: Dioxin receptor deficiency impairs angiogenesis by a mechanism involving VEGF-A depletion in the endothelium and transforming growth factor-beta overexpression in the stroma. J Biol Chem 284: 25135-25148, 2009.
83. Kawajiri K, Watanabe J, Eguchi H, Nakachi K, Kiyohara C and Hayashi S: Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics 5: 151-158, 1995.
84. Anttila S, Lei XD, Elovaara E, Karjalainen A, Sun W, Vainio H and Hankinson O: An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribable to polymorphisms in the AHR, ARNT, or CYP1A1 genes. Pharmacogenetics 10: 741-751, 2000.
85. Anttila S, Tuominen P, Hirvonen A, Nurminen M, Karjalainen A, Hankinson O and Elovaara E: CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor. Pharmacogenetics 11: 501-509, 2001. (Pubitemid 32780554)
86. Cauchi S, Stucker I, Cenee S, Kremers P, Beaune P and Massaad-Massade L: Structure and polymorphisms of human aryl hydrocarbon receptor repressor (AhRR) gene in a French population: Relationship with CYP1A1 inducibility and lung cancer. Pharmacogenetics 13: 339-347, 2003. (Pubitemid 36724527)
87. Cauchi S, Stucker I, Solas C, Laurent-Puig P, Cenee S, Hemon D, Jacquet M, Kremers P, Beaune P and Massaad-Massade L: Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. Carcinogenesis 22: 1819-1824, 2001. (Pubitemid 33064847)
88. Kim JH, Kim H, Lee KY, Kang JW, Lee KH, Park SY, Yoon HI, Jheon SH, Sung SW and Hong YC: Aryl hydrocarbon receptor gene polymorphisms affect lung cancer risk. Lung Cancer 56: 9-15, 2007. (Pubitemid 46389365)
89. Cauffiez C, Lo-Guidice JM, Quaranta S, Allorge D, Chevalier D, Cenee S, Hamdan R, Lhermitte M, Lafitte JJ, Libersa C, Colombel JF, Stucker I and Broly F: Genetic polymorphism of the human cytochrome CYP2A13 in a French population: Implication in lung cancer susceptibility. Biochem Biophys Res Commun 317: 662-669, 2004. (Pubitemid 38452534)
90. Chen D, Tian T, Wang H, Liu H, Hu Z, Wang Y, Liu Y, Ma H, Fan W, Miao R, Sun W, Qian J, Jin L, Wei Q, Shen H, Huang W and Lu D: Association of human aryl hydrocarbon receptor gene polymorphisms with risk of lung cancer among cigarette smokers in a Chinese population. Pharmacogenet Genomics 19: 25-34, 2009.